During the webinar, participants will gain an understanding of how connected inhalers can help to pave the way to be a win-win situation for patients, the pharmaceutical industry and healthcare providers. Participants will also see how important flow inhalation measurement technology is in response to the most common mistakes while using an inhaler.
Respiratory infections continue to have the highest incidence rate in Europe. And when asthma is considered, there has been a sharp increase in global cases, morbidity, and mortality rates, as well as being an economic burden over the last 40 years. More than 300 million people have asthma worldwide. These figures demonstrate that despite the efforts of the past few years, the reduction of the incidence of asthma has not been achieved yet.
Connected devices – such as smart inhalers – offer a great opportunity to increase adherence and improve the quality of life of patients.
The digitalisation of healthcare can be beneficial. If carefully designed and thoughtfully implemented, digital health has the potential to improve health and care outcomes alike. Health information is fast becoming readily available because of the transfer of digital health data. As a result, higher-quality therapeutic decision-making as well as the mechanism and efficiency quality of health services are improved.
Presspart will present the latest development for their connected inhaler and demonstrate how the integration of a diagnostic unit into the inhaler could help to anticipate asthma attacks, aid therapeutic decision-making, and improve healthcare resource allocation.
Business Development Manager
Thorsten Lehmann is a Business Development Manager. With a background in International Management and an additional degree as a pharmaceutical consultant, his career focuses on the Health Care Industry. Thorsten worked for one of the world’s leading providers of healthcare products and now leads the development of solutions for the smart drug delivery system market at H&T Presspart.
Business Development Director
Dr Anselm Ebert (PhD) is currently the Business Development Director at H&T Presspart, the leading supplier of respiratory drug delivery components and devices. Dr Ebert oversees the strategic management of the new product development process at H&T Presspart, and has been instrumental in the introduction of the company’s range of dry powder inhalers to the market.
Dr Ebert has previously worked as a Senior Business Consultant and before joining H&T Presspart was Director of Product Development at Hartmann AG. He acquired his PhD at the field of Neuroscience from the University of Hamburg and Edinburgh.
Key Learning Objectives
Understand the increasing demand for digital solutions towards patient centricity and empowerment
Understand how the increase of adherence rates can be translated into improved health outcomes
Understand the use of flow sensor technology in asthma management
Learn about H&T Presspart’s capabilities in manufacturing smart drug delivery devices